PX7 Tablets contain a combination of Myo-Inositol 600 mg and Metformin Hydrochloride 500 mg in a sustained-release formulation. This combination is used under medical supervision as part of the management of certain metabolic and hormonal concerns associated with PCOS (Polycystic Ovary Syndrome). Myo-Inositol is involved in cellular signalling and metabolic processes, while metformin helps improve the body’s response to insulin and supports better glucose regulation.
PX7 Tablets should be taken only according to the dosage and duration prescribed by a qualified healthcare professional. Regular medical follow-up may be recommended to monitor response and ensure appropriate use.
Key Benefits of PX7 Tablets
- Contains Myo-Inositol 600 mg and Metformin Hydrochloride 500 mg SR.
- Supports insulin sensitivity and healthy glucose metabolism.
- May be prescribed as part of PCOS management.
- Supports metabolic health in women with insulin resistance associated with PCOS.
- Myo-Inositol supports normal cellular and hormonal signalling.
- Sustained-release metformin provides gradual release of the active ingredient.
- May support the overall management of metabolic aspects of PCOS when prescribed by a doctor.
- Convenient tablet formulation for use as directed by a healthcare professional.
